Skip to content
OpenCapital
Get started

Utah Medical Products UTMD Finite-Lived Patents, Gross

Finite-Lived Patents, Gross at other companies

PDE
Pro-Dex, Inc.PDEX
——

Other financials

Income statement

See full
Revenue$8.7M-10.2%
Gross profit$5.3M-4.6%
Operating income$2.6M-18.6%
Net income$2.6M-14.4%
EPS (diluted)$0.82-10.9%

Balance sheet

See full
Cash & equivalents$87.4M+4.9%
Total debt$210.0K—
Total equity$120.4M+2.8%
Total assets$124.4M+1.5%

Cash flow

See full
Operating cash flow$3.1M-30.4%
CapEx$130.0K-29.3%
Free cash flow$3.0M-30.4%

Valuation

See full
Market cap$219.63M+26.4%
Enterprise value$132.44M+42.5%
P/E20.3×+6.4×
P/S5.9×+1.4×

Profitability

See full
Gross margin57.9%-0.4pp
Operating margin28.8%-3.9pp
Net margin28.9%-4.1pp
FCF margin34.7%0.0pp

Returns & leverage

See full
Return on equity9.1%-1.4pp
Debt / equity0×—
Current ratio28.6×+6.3×

Where this comes from

Reported directly by Utah Medical Products in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedPatentsGross.

The official record: Utah Medical Products’s 10-K, filed March 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Utah Medical Products's finite-lived patents, gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Utah Medical Products's finite-lived patents, gross?
Utah Medical Products (UTMD) reported finite-lived patents, gross of $2.22M in Q4 2025.
How has Utah Medical Products's finite-lived patents, gross changed year-over-year?
Utah Medical Products's finite-lived patents, gross increased by 0.5% year-over-year, from $2.21M to $2.22M.
What is the long-term trend for Utah Medical Products's finite-lived patents, gross?
Over 5 years (2020 to 2025), Utah Medical Products's finite-lived patents, gross has grown at a 0.2% compound annual growth rate (CAGR), from $2.2M to $2.22M.
What does finite-lived patents, gross mean?
This represents the total historical cost of acquired or developed patents that provide the company with exclusive rights to its proprietary medical technologies. These assets are amortized over their useful lives, reflecting the value of the company's intellectual property portfolio. It is a key indicator of the company's investment in innovation and its ability to maintain a competitive advantage.